Competition Authority Investigates Teva Over Generic Competition Practices
What happened
The Competition Board initiated an investigation into Teva Pharmaceutical Industries Ltd., Teva İlaçları San. ve Tic. AŞ, and Teva Pharmaceuticals Europe B.V. to determine if Teva violated competition law by restricting generic competition practices. The investigation specifically examines the strategic use of divisional patent procedures and related withdrawal practices by Teva. These practices concern divisional patent applications for manufacturing processes and dosage regimens filed after the basic molecule patent expired.
From gide.com
Why it matters
The inquiry focuses on whether Teva’s patent applications made it more difficult for equivalent medicines to enter the market. The investigation also looks into whether Teva attempted to create a misleading impression before health authorities regarding the safety and effectiveness of competing products.
From gide.com
Who's involved
- Teva Pharmaceutical Industries Ltd.Israeli pharmaceutical company under investigation for generic competition practices.
- Competition AuthorityState authority conducting the investigation into Teva's competition practices.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Teva Pharmaceutical Industries Ltd.Speculative
Teva Pharmaceutical Industries Ltd. could face regulatory action that might impact the revenue generated from its core generic competition business.
Keep exploring
The entities involved
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
-
Competition Authority
state authority of Estonia
Nothing else this week.